BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé will retire in December, when he will be succeeded by Genentech CEO Alexander Hardy. The transition comes with BioMarin in the early stages of the commercial launch of Roctavian, the first FDA-approved hemophilia A gene therapy.
San Rafael: BioMarin Pharmaceutical Inc. has recently announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO (vosoritide) for Injection, indicated to.